Imugene enters into agreement with Merck KGaA and Pfizer to evaluate HER-Vaxx – Avelumab for the treatment of gastric cancer
(RTTNews) – Imugene (IMU.AX) announced on Wednesday that it has entered into a new clinical trial supply agreement with Merck KgaA (MKGAY.PK) and Pfizer Inc. (PFE) to assess the safety and efficacy of HER -Vaxx by Imugene in combination with avelumab, an immune checkpoint inhibitor targeting PD-L1, in patients with HER-2 positive gastric cancer.
Imugene HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumors that overexpress the HER-2 / neu receptor, such as cancers of the stomach, breast, ovary, lung and pancreas.
Avelumab, marketed under the name BAVENCIO, is co-developed and co-marketed by Merck KgaA and Pfizer.
neoHERIZON, which is an open-label, multicenter, randomized, phase 2 clinical trial, will evaluate the safety and efficacy of perioperative HER-Vaxx in combination with chemotherapy with or without avelumab compared to chemotherapy alone in patients with HER -2 positive gastric or adenocarcinoma of the gastroesophageal junction.
Under the terms of the agreement, Imugene will sponsor the study and fund the clinical study from existing budgets and resources. Merck KGaA and Pfizer will provide avelumab for the duration of the study.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.